PIK3CD and cancer: Currently, no PI3K inhibitors have been approved specifically for neuroinflammatory diseases, though several agents, such as duvelisib and copanlisib (for cancer), are in advanced clinical trials and could potentially be repurposed for CNS diseases [181].